Showing results (1301-1310 of 2,086) with videos related to
Sort By:
Pageof 209
Free Radical Biology & Medicine|May 29, 2002
The vascular NADPH oxidase subunit p47phox is involved in redox-mediated gene expressionRalf P Brandes, Francis J Miller, Stefani Beer, et al.Biomaterials|April 20, 2006
In vitro re-endothelialization of detergent decellularized heart valves under simulated physiological dynamic conditionsArtur Lichtenberg, Igor Tudorache, Serghei Cebotari, et al.Journal of Cardiovascular Pharmacology|December 1, 1994
Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbitsA Mügge, R P Brandes, R H Böger, et al.European Journal of Cancer (Oxford, England : 1990)|January 10, 2012
Epidemiology of glial and non-glial brain tumours in EuropeEmanuele Crocetti, Annalisa Trama, Charles Stiller, et al.Cephalalgia : an International Journal of Headache|October 9, 2009
Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacksJ L Brandes, A c Poole, M Kallela, et al.Cancer Treatment Reports|January 1, 1985
Peptichemio in pretreated patients with ovarian cancerA Paccagnella, F Tredese, L Salvagno, et al.Urology|April 29, 2014
Urethrography interpretation skills of urology and radiology residents at tertiary care medical centersJairam R Eswara, Joseph B Song, Andrew J Chang, et al.Frontiers in Pediatrics|February 24, 2023
Resolving inherited and de novo germline predisposing sequence variants by means of whole exome trio analyses in childhood hematological malignanciesTriantafyllia Brozou, Layal Yasin, Danielle Brandes, et al.Proceedings of the National Academy of Sciences of the United States of America|August 16, 2000
An endothelium-derived hyperpolarizing factor distinct from NO and prostacyclin is a major endothelium-dependent vasodilator in resistance vessels of wild-type and endothelial NO synthase knockout miceR P Brandes, F H Schmitz-Winnenthal, M Félétou, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 13, 2001
Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II studyA A Brandes, M Ermani, U Basso, et al.Pageof 209